Back to top
more

Epizyme, Inc. (EPZM)

(Delayed Data from NSDQ)

$12.10 USD

12.10
622,659

+0.19 (1.60%)

Updated May 3, 2019 04:00 PM ET

After-Market: $12.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Epizyme Stock Up on Positive Advisory Votes for Tazemetostat

by Zacks Equity Research

Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Ekta Bagri headshot

5 Biotech Stocks That Have More Than Doubled This Year

by Ekta Bagri

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Moving Average Crossover Alert: Epizyme

by Zacks Equity Research

Epizyme is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Epizyme (EPZM) Is Up 10.29% in One Week: What You Should Know

by Zacks Equity Research

Does Epizyme (EPZM) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

Indrajit Bandyopadhyay headshot

5 Biotech Stocks Up More Than 100% This Year So Far

by Indrajit Bandyopadhyay

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

Epizyme Announces FDA Committee Review of Tazemetostat NDA

by Zacks Equity Research

Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.

Implied Volatility Surging for Epizyme (EPZM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

Epizyme (EPZM) Is Up 6.9% in One Week: What You Should Know

by Zacks Equity Research

Does Epizyme (EPZM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Epizyme, Inc. (EPZM) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Epizyme, Inc. (EPZM).

Epizyme (EPZM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 25.93% and 3.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

by Zacks Equity Research

Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 0.00% and 424.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

by Zacks Equity Research

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme Announces Positive Interim Data on Lead Candidate

by Zacks Equity Research

Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.

Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

by Zacks Equity Research

Epizyme (EPZM) submits an NDA filing for tazemetostat to the FDA with an objective to treat patients suffering metastatic epithelioid sarcoma, not eligible for curative surgery. Shares inch up.

Will Epizyme to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Epizyme.

Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?

by Zacks Equity Research

Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.

Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?